Insmed Incorporated (NASDAQ:INSM) Stock Holdings Increased by Rhumbline Advisers

Rhumbline Advisers raised its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 5.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 303,557 shares of the biopharmaceutical company's stock after buying an additional 15,220 shares during the quarter. Rhumbline Advisers owned about 0.17% of Insmed worth $23,158,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after buying an additional 1,075,796 shares during the last quarter. Darwin Global Management Ltd. boosted its holdings in shares of Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after purchasing an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Insmed by 1.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock worth $877,113,000 after purchasing an additional 123,429 shares during the last quarter. Capital International Investors boosted its holdings in shares of Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after purchasing an additional 593,206 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after purchasing an additional 273,759 shares during the last quarter.

Insiders Place Their Bets

In other news, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total transaction of $479,192.80. Following the sale, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at approximately $16,412,107.84. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Alexander Smith sold 1,879 shares of Insmed stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $73.50, for a total value of $138,106.50. Following the sale, the insider now directly owns 67,718 shares in the company, valued at approximately $4,977,273. The trade was a 2.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 162,994 shares of company stock worth $11,320,938 over the last quarter. 3.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on INSM. Jefferies Financial Group began coverage on Insmed in a report on Tuesday, May 13th. They set a "buy" rating and a $105.00 price objective on the stock. UBS Group decreased their price objective on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company raised their price objective on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Royal Bank of Canada restated an "outperform" rating and set a $100.00 price objective on shares of Insmed in a report on Wednesday, March 19th. Finally, Guggenheim reiterated a "buy" rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Insmed has an average rating of "Moderate Buy" and a consensus price target of $96.73.

Insmed Stock Up 1.2%

Shares of INSM traded up $0.88 during midday trading on Friday, reaching $73.62. 1,558,246 shares of the company were exchanged, compared to its average volume of 2,072,473. The stock has a 50-day moving average price of $69.28 and a 200-day moving average price of $73.03. The company has a market cap of $13.41 billion, a price-to-earnings ratio of -13.17 and a beta of 0.80. Insmed Incorporated has a 1-year low of $55.74 and a 1-year high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.06) EPS. Research analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.